{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,7]],"date-time":"2026-10-07T06:20:44Z","timestamp":1791354044608,"version":"4.3.1"},"reference-count":39,"publisher":"Oxford University Press (OUP)","issue":"Supplement_3","funder":[{"name":"Joint Program Committee","award":["DM178016"],"award-info":[{"award-number":["DM178016"]}]},{"name":"Joint Program Committee","award":["DM178016"],"award-info":[{"award-number":["DM178016"]}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2024,8,19]]},"abstract":"<jats:title>ABSTRACT<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Introduction<\/jats:title>\n                    <jats:p>Exposure to high doses of ionizing radiation can result in hematopoietic acute radiation syndrome. Currently, there is no radiation medical countermeasure approved by the U.S. FDA which can be used before radiation exposure to protect exposed individuals. Here we aimed to evaluate the therapeutic potential of an aqueous suspension of synthetic genistein nanoparticles (BIO 300) as a radioprotectant in a pilot efficacy study using a nonhuman primate model of total body irradiation.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Materials and Methods<\/jats:title>\n                    <jats:p>Eight rhesus macaques were divided into two groups; four received vehicle and four received BIO 300 Injectable Suspension 24\u2009h before 5.8\u2009Gy total-body irradiation. Survival, blood cell counts, blood chemistry, and clinical parameters were monitored over the 60\u2009days of the study. Tissues were collected at necropsy 60\u2009days post-irradiation or from animals that met unscheduled euthanasia criteria and subjected to histopathological analysis. Tissues analyzed included the duodenum, jejunum, ileum, sternum, lung, heart, liver, kidney, spleen, gut-associated lymphoid tissue, and urinary bladder.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>In this pilot study, all BIO 300 Injectable Suspension treated animals survived to day 60, while only 50% of the vehicle-treated animals survived. We found that BIO 300 Injectable Suspension did not mediate an improvement in blood cell counts (e.g., neutrophils, platelets, white blood cells). However, BIO 300 Injectable Suspension treated animals had a lower incidence of fever and febrile neutropenia, were able to better maintain their body weight post radiation exposure, and exhibited less anemia and faster recovery from anemia. Histopathological analysis revealed that BIO 300-treated animals had less irradiation-induced damage to the sternum and other tissues compared to vehicle controls.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>BIO 300\u2019s mechanism of action is complex and protection against irradiation is attainable without much improvement in the complete blood count (CBC) profile. BIO 300\u2019s mechanism for radioprotection involves multiple biological pathways and systems.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1093\/milmed\/usae156","type":"journal-article","created":{"date-parts":[[2024,3,20]],"date-time":"2024-03-20T20:25:58Z","timestamp":1710966358000},"page":"390-398","source":"Crossref","is-referenced-by-count":11,"title":["BIO 300: A Prophylactic Radiation Countermeasure for Acute Radiation Syndrome"],"prefix":"10.1093","volume":"189","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-6631-3849","authenticated-orcid":false,"given":"Vijay K","family":"Singh","sequence":"first","affiliation":[{"name":"Department of Pharmacology and Molecular Therapeutics, F. Edward H\u00e9bert School of Medicine, Uniformed Services University of the Health Sciences , Bethesda, MD 20814, USA"},{"name":"Armed Forces Radiobiology Research Institute, Uniformed Services University of the Health Sciences , Bethesda, MD 20814, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2683-4383","authenticated-orcid":false,"given":"Artur A","family":"Serebrenik","sequence":"additional","affiliation":[{"name":"Humanetics Corporation , Minneapolis, MN 55435, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7613-7455","authenticated-orcid":false,"given":"Stephen Y","family":"Wise","sequence":"additional","affiliation":[{"name":"Department of Pharmacology and Molecular Therapeutics, F. Edward H\u00e9bert School of Medicine, Uniformed Services University of the Health Sciences , Bethesda, MD 20814, USA"},{"name":"Armed Forces Radiobiology Research Institute, Uniformed Services University of the Health Sciences , Bethesda, MD 20814, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2645-7570","authenticated-orcid":false,"given":"Sarah A","family":"Petrus","sequence":"additional","affiliation":[{"name":"Department of Pharmacology and Molecular Therapeutics, F. Edward H\u00e9bert School of Medicine, Uniformed Services University of the Health Sciences , Bethesda, MD 20814, USA"},{"name":"Armed Forces Radiobiology Research Institute, Uniformed Services University of the Health Sciences , Bethesda, MD 20814, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7942-2497","authenticated-orcid":false,"given":"Oluseyi O","family":"Fatanmi","sequence":"additional","affiliation":[{"name":"Department of Pharmacology and Molecular Therapeutics, F. Edward H\u00e9bert School of Medicine, Uniformed Services University of the Health Sciences , Bethesda, MD 20814, USA"},{"name":"Armed Forces Radiobiology Research Institute, Uniformed Services University of the Health Sciences , Bethesda, MD 20814, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6643-6259","authenticated-orcid":false,"given":"Michael D","family":"Kaytor","sequence":"additional","affiliation":[{"name":"Humanetics Corporation , Minneapolis, MN 55435, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2024,8,19]]},"reference":[{"issue":"6","key":"2024082004110828400_R1","doi-asserted-by":"publisher","first-page":"496","DOI":"10.1097\/MOH.0000000000000380","article-title":"Medical and policy considerations for nuclear and radiation accidents, incidents and terrorism","volume":"24","author":"Gale","year":"2017","journal-title":"Curr Opin Hematol"},{"key":"2024082004110828400_R2","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1259\/bjr\/70312032","article-title":"The pathology of multi-organ involvement: two autopsy cases from the Tokai-mura criticality accident","volume":"27","author":"Uozaki","year":"2005","journal-title":"BJR Suppl"},{"key":"2024082004110828400_R3","doi-asserted-by":"publisher","first-page":"462","DOI":"10.1097\/01.HP.0000278843.27969.74","article-title":"Health effects in those with acute radiation sickness from the Chernobyl accident","volume":"93(5)","author":"Mettler","year":"2007","journal-title":"Health Phys"},{"key":"2024082004110828400_R4","article-title":"Radiological and nuclear emergency preparedness information from FDA","author":"U.S. Food and Drug Administration","year":"2023"},{"key":"2024082004110828400_R5","article-title":"Animal rule approvals","author":"U.S. Food and Drug Administration","year":"2022"},{"key":"2024082004110828400_R6","doi-asserted-by":"publisher","first-page":"1246","DOI":"10.1056\/NEJMsr1714289","article-title":"Are we prepared for nuclear terrorism?","volume":"378(13)","author":"Gale","year":"2018","journal-title":"N Engl J Med"},{"issue":"5","key":"2024082004110828400_R7","doi-asserted-by":"publisher","first-page":"429","DOI":"10.1080\/13543784.2020.1757648","article-title":"BIO 300: a promising radiation countermeasure under advanced development for acute radiation syndrome and the delayed effects of acute radiation exposure","volume":"29","author":"Singh","year":"2020","journal-title":"Expert Opin Investig Drugs"},{"issue":"5","key":"2024082004110828400_R8","doi-asserted-by":"publisher","first-page":"958","DOI":"10.1080\/09553002.2021.1981556","article-title":"A novel oral formulation of BIO 300 confers prophylactic radioprotection from acute radiation syndrome in mice","volume":"98","author":"Singh","year":"2022","journal-title":"Int J Radiat Biol"},{"issue":"3","key":"2024082004110828400_R9","doi-asserted-by":"publisher","first-page":"294","DOI":"10.1667\/RADE-22-00142.1","article-title":"The radioprotectant, BIO 300, protects the lungs from total-body irradiation injury in C57L\/J mice","volume":"199","author":"Singh","year":"2023","journal-title":"Radiat Res"},{"key":"2024082004110828400_R10","first-page":"23","author":"Landauer","year":"2009"},{"issue":"12","key":"2024082004110828400_R11","doi-asserted-by":"publisher","first-page":"1401","DOI":"10.1016\/j.intimp.2009.08.012","article-title":"Effects of genistein administration on cytokine induction in whole-body gamma irradiated mice","volume":"9","author":"Singh","year":"2009","journal-title":"Int Immunopharmacol"},{"issue":"2","key":"2024082004110828400_R12","doi-asserted-by":"publisher","first-page":"348","DOI":"10.1016\/j.intimp.2012.12.029","article-title":"Enhanced hematopoietic protection from radiation by the combination of genistein and captopril","volume":"15","author":"Day","year":"2013","journal-title":"Int Immunopharmacol"},{"issue":"3","key":"2024082004110828400_R13","doi-asserted-by":"publisher","first-page":"308","DOI":"10.1093\/jrr\/rrz014","article-title":"Mechanism and therapeutic window of a genistein nanosuspension to protect against hematopoietic-acute radiation syndrome","volume":"60","author":"Landauer","year":"2019","journal-title":"J Radiat Res"},{"issue":"4","key":"2024082004110828400_R14","doi-asserted-by":"publisher","first-page":"701","DOI":"10.1080\/17460441.2019.1604674","article-title":"Drug discovery strategies for acute radiation syndrome","volume":"14","author":"Singh","year":"2019","journal-title":"Expert Opin Drug Discov"},{"key":"2024082004110828400_R15","volume-title":"Guide for the Care and Use of Laboratory Animals","author":"National Research Council of the National Academy of Sciences","year":"2011","edition":"8th"},{"issue":"6","key":"2024082004110828400_R16","doi-asserted-by":"publisher","first-page":"599","DOI":"10.1667\/RADE-22-00101.1","article-title":"Determination of lethality curve for cobalt-60 gamma-radiation source in rhesus macaques using subject-based supportive care","volume":"198","author":"Singh","year":"2022","journal-title":"Radiat Res"},{"key":"2024082004110828400_R17","doi-asserted-by":"publisher","DOI":"10.3390\/ijms20051231","article-title":"Pharmacokinetic and metabolomic studies with BIO 300, a nanosuspension of genistein, in a nonhuman primate model","volume":"20(13)","author":"Cheema","year":"2019","journal-title":"Int J Mol Sci"},{"key":"2024082004110828400_R18","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-020-76494-4","article-title":"Comparative proteomic analysis of serum from nonhuman primates administered BIO 300: a promising radiation countermeasure","volume":"10(1)","author":"Girgis","year":"2020","journal-title":"Sci Rep"},{"issue":"3","key":"2024082004110828400_R19","doi-asserted-by":"publisher","first-page":"285","DOI":"10.1667\/RR14127.1","article-title":"Radioprotective efficacy of gamma-tocotrienol in nonhuman primates","volume":"185","author":"Singh","year":"2016","journal-title":"Radiat Res"},{"key":"2024082004110828400_R20","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-021-85669-6","article-title":"Transcriptome of rhesus macaque (Macaca mulatta) exposed to total-body irradiation","volume":"11(1)","author":"Li","year":"2021","journal-title":"Sci Rep"},{"key":"2024082004110828400_R21","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-021-91067-9","article-title":"Analysis of the metabolomic profile in serum of irradiated nonhuman primates treated with Ex-Rad, a radiation countermeasure","volume":"11(1)","author":"Li","year":"2021","journal-title":"Sci Rep"},{"key":"2024082004110828400_R22","doi-asserted-by":"publisher","DOI":"10.1128\/aac.00546-22","article-title":"Model for evaluating antimicrobial therapy to prevent life-threatening bacterial infections following exposure to a medically significant radiation dose","volume":"66(10)","author":"Phipps","year":"2022","journal-title":"Antimicrob Agents Chemother"},{"key":"2024082004110828400_R23","article-title":"AVMA Guidelines for the Euthanasia of Animals: 2020 Edition","author":"American Veterinary Medical Association","year":"2020"},{"key":"2024082004110828400_R24","doi-asserted-by":"publisher","first-page":"537","DOI":"10.1358\/dot.2015.51.9.2386730","article-title":"Filgrastim for the treatment of hematopoietic acute radiation syndrome","volume":"51(9)","author":"Farese","year":"2015","journal-title":"Drugs Today (Barc)"},{"key":"2024082004110828400_R25","doi-asserted-by":"publisher","first-page":"679","DOI":"10.1358\/dot.2018.54.11.2899370","article-title":"An update on sargramostim for treatment of acute radiation syndrome","volume":"54(11)","author":"Singh","year":"2018","journal-title":"Drugs Today (Barc)"},{"key":"2024082004110828400_R26","doi-asserted-by":"publisher","first-page":"1526","DOI":"10.1080\/09553002.2021.1969054","article-title":"Radiation countermeasures for hematopoietic acute radiation syndrome: growth factors, cytokines and beyond","volume":"97(11)","author":"Singh","year":"2021","journal-title":"Int J Radiat Biol"},{"key":"2024082004110828400_R27","doi-asserted-by":"publisher","first-page":"643","DOI":"10.1667\/RR13940.1","article-title":"Pegfilgrastim improves survival of lethally irradiated nonhuman primates","volume":"183(6)","author":"Hankey","year":"2015","journal-title":"Radiat Res"},{"key":"2024082004110828400_R28","doi-asserted-by":"publisher","first-page":"191","DOI":"10.1667\/RADE-20-00131.1","article-title":"Sargramostim (rhu GM-CSF) improves survival of non-human primates with severe bone marrow suppression after acute, high-dose, whole-body irradiation","volume":"195(2)","author":"Clayton","year":"2021","journal-title":"Radiat Res"},{"key":"2024082004110828400_R29","doi-asserted-by":"publisher","first-page":"S100","DOI":"10.1080\/09553002.2019.1673499","article-title":"Efficacy of delayed administration of sargramostim up to 120 hours post exposure in a nonhuman primate total body radiation model","volume":"97(Suppl 1)","author":"Zhong","year":"2021","journal-title":"Int J Radiat Biol"},{"key":"2024082004110828400_R30","doi-asserted-by":"publisher","first-page":"133","DOI":"10.1358\/dot.2022.58.3.3367994","article-title":"An update on romiplostim for treatment of acute radiation syndrome","volume":"58(3)","author":"Singh","year":"2022","journal-title":"Drugs Today"},{"key":"2024082004110828400_R31","doi-asserted-by":"publisher","first-page":"705","DOI":"10.1016\/j.ijrobp.2023.05.008","article-title":"Survival and hematologic benefits of romiplostim after acute radiation exposure supported FDA approval under the animal rule","volume":"17(1)","author":"Bunin","year":"2023","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"2024082004110828400_R32","doi-asserted-by":"publisher","first-page":"89","DOI":"10.1667\/RR3049.1","article-title":"Filgrastim improves survival in lethally irradiated nonhuman primates","volume":"179(1)","author":"Farese","year":"2013","journal-title":"Radiat Res"},{"issue":"2","key":"2024082004110828400_R33","doi-asserted-by":"publisher","first-page":"404","DOI":"10.1016\/j.ijrobp.2023.08.048","article-title":"Multicenter phase 1b\/2a clinical trial of radioprotectant BIO 300 oral suspension for patients with non-small cell lung cancer receiving concurrent chemoradiotherapy","volume":"118","author":"Simone","year":"2024","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"2024082004110828400_R34","doi-asserted-by":"publisher","DOI":"10.1088\/1361-6498\/ac7d18","article-title":"Medical management of acute radiation syndrome","volume":"42(3)","author":"Dainiak","year":"2022","journal-title":"J Radiol Prot"},{"key":"2024082004110828400_R35","doi-asserted-by":"publisher","first-page":"121","DOI":"10.1667\/RR14406.1","article-title":"A review of radiation-induced coagulopathy and new findings to support potential prevention strategies and treatments","volume":"186(2)","author":"Kennedy","year":"2016","journal-title":"Radiat Res"},{"key":"2024082004110828400_R36","doi-asserted-by":"publisher","first-page":"400","DOI":"10.1016\/j.ijrobp.2019.05.062","article-title":"BIO 300, a nanosuspension of genistein, mitigates radiation-induced erectile dysfunction and sensitizes human prostate cancer xenografts to radiation therapy","volume":"105(2)","author":"Jackson","year":"2019","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"2024082004110828400_R37","doi-asserted-by":"publisher","DOI":"10.1186\/s42523-021-00132-1","article-title":"Microbiome study in irradiated mice treated with BIO 300, a promising radiation countermeasure","volume":"3(1)","author":"Cheema","year":"2021","journal-title":"Anim Microbiome"},{"key":"2024082004110828400_R38","doi-asserted-by":"publisher","first-page":"905","DOI":"10.1152\/physrev.00026.2006","article-title":"Estrogen receptors: how do they signal and what are their targets","volume":"87(3)","author":"Heldring","year":"2007","journal-title":"Physiol Rev"},{"key":"2024082004110828400_R39","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1016\/j.steroids.2014.06.012","article-title":"Estrogen receptors alpha (ER alpha) and beta (ER beta): subtype-selective ligands and clinical potential","volume":"90","author":"Paterni","year":"2014","journal-title":"Steroids"}],"container-title":["Military Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/milmed\/article-pdf\/189\/Supplement_3\/390\/58855705\/usae156.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/milmed\/article-pdf\/189\/Supplement_3\/390\/58855705\/usae156.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,8,20]],"date-time":"2024-08-20T00:14:29Z","timestamp":1724112869000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/milmed\/article\/189\/Supplement_3\/390\/7735878"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,8,19]]},"references-count":39,"journal-issue":{"issue":"Supplement_3","published-online":{"date-parts":[[2024,8,19]]},"published-print":{"date-parts":[[2024,8,19]]}},"URL":"https:\/\/doi.org\/10.1093\/milmed\/usae156","relation":{},"ISSN":["0026-4075","1930-613X"],"issn-type":[{"value":"0026-4075","type":"print"},{"value":"1930-613X","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2024,9]]},"published":{"date-parts":[[2024,8,19]]}}}